Results 11 to 20 of about 33,909 (225)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy

OncoImmunology, 2020
Chimeric antigen receptor (CAR) T cells show remarkable therapeutic effects in some hematological malignancies. However, CAR T cells can also cause life-threatening side effects.
Anja Feldmann, Anja Hoffmann, Ralf Bergmann, Stefanie Koristka, Nicole Berndt, Claudia Arndt, Liliana Rodrigues Loureiro, Enrico Kittel-Boselli, Nicola Mitwasi, Alexandra Kegler, Chris Lamprecht, Karla Elizabeth González Soto, Michael Bachmann   +12 more
doaj   +1 more source

Targeted radiotherapy of neuroblastoma: future directions [PDF]

, 2017
No abstract ...
Gaze, Mark N., Mairs, Robert, Nile, Donna L., Rae, Colin, Tesson, Mathias   +4 more
core   +2 more sources

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

APPLICABILITY OF BACTERIAL ENDOTOXIN TEST (BET) FOR SOME RADIOPHARMACEUTICAL STERILE KITS BY THE USE OF TACHYPLEUS AMEBOCYTE LYSATE (TAL)

Jurnal Farmasi Sains dan Komunitas, 2019
The application of bacterial endotoxin test (BET) using TAL reagent on radiopharmaceutical kits is very important to conduct. The radiopharmaceutical kits that will be tested are macro aggregated albumin (MAA), tetrofosmin and ethambutol kits.
Amal Rezka Putra, Enny Lestari, Dede Kurniasih, Karyadi Karyadi, Endang Sarmini, Arni Aries   +5 more
doaj   +1 more source

Simultaneous Visualization of ¹⁶¹Tb- and ¹⁷⁷Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

Pharmaceutics, 2021
The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes.
Francesca Borgna, Patrick Barritt, Pascal V. Grundler, Zeynep Talip, Susan Cohrs, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller   +9 more
doaj   +1 more source

Radiopharmaceutical Therapy [PDF]

Health Physics, 2019
Abstract Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, peptides, and small molecules) or that concentrate in tumors through natural physiological mechanisms that occur predominantly in neoplastic cells.
openaire   +2 more sources

The Use of Low Ammonia Concentration in the Radiochemical Purity Test of [153Sm]Sm-EDTMP by Using the Thin Layer Chromatography Method [PDF]

Journal of Pure and Applied Chemistry Research, 2021
Radiochemical purity testing of [153Sm]Sm-EDTMP usually uses the Thin Layer Chromatography method. The mobile phase used is a mixture of 25% ammonia and water. However, the lowest ratio of 25% ammonia in the mobile phase is unknown.
Amal Rezka Putra, Khoirunnisa Fauziah Asyikin, Robertus Dwi Hendarto, Agus Ariyanto, Enny Lestari, Sumandi Juliyanto, Ahsanal Fikri   +6 more
doaj  

Aptamer-based therapeutics and their potential in radiopharmaceutical design [PDF]

, 2007
Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications.
Ferreira, Catia S. M., Missailidis, Sotiris   +1 more
core   +3 more sources

Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files

Frontiers in Oncology, 2019
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity.
Charles A. Kunos, Jacek Capala, Susan Percy Ivy   +2 more
doaj   +1 more source